2025
The VEGF/VEGFR2 system in ovarian cancer: From functional to pharmacological significance
Grillo E, Romani C, Ettorre V, Santin A, Mitola S. The VEGF/VEGFR2 system in ovarian cancer: From functional to pharmacological significance. Biochimica Et Biophysica Acta (BBA) - Reviews On Cancer 2025, 1880: 189374. PMID: 40516635, DOI: 10.1016/j.bbcan.2025.189374.Peer-Reviewed Original ResearchVascular endothelial growth factor receptor 2Ovarian cancerOvarian cancer cellsCancer-associated fibroblastsAnti-angiogenicVEGF/VEGFR2 axisTumor cellsCancer cellsProgression of ovarian cancerVascular endothelial growth factor receptor 2 pathwaysTreating ovarian cancerEndothelial growth factor receptor 2Tyrosine kinase receptorsIntracellular signaling cascadesOC therapyImmune cellsPreclinical studiesReceptor 2Poor responseClinical studiesNon-canonical ligandsStromal onesMolecular landscapeKinase receptorsVEGF/VEGFR2
2024
Abstract 2759: Transcriptional intra-tumoral heterogeneity of putative therapeutic targets in colorectal cancer peritoneal metastases
Zhao J, Ong J, Chia D, Teo M, Tan Q, Ng G, Tan J, Ma H, Ong X, Tay S, Tan P, Sundar R. Abstract 2759: Transcriptional intra-tumoral heterogeneity of putative therapeutic targets in colorectal cancer peritoneal metastases. Cancer Research 2024, 84: 2759-2759. DOI: 10.1158/1538-7445.am2024-2759.Peer-Reviewed Original ResearchColorectal cancer peritoneal metastasesCRC PMPeritoneal metastasisColorectal cancerIntra-tumor heterogeneitySystemic regimensTherapeutic targetAmerican Association for Cancer Research annual meetingsPrognosis of peritoneal metastasisResistant to systemic chemotherapyPlasma-peritoneal barrierOncological surgical resectionColorectal cancer patientsSystemic chemotherapySurgical resectionPalliative surgerySystemic therapyAntineoplastic therapyPotential therapeutic targetExploratory laparotomyTranscoelomic metastasisPoor prognosisFFPE tissue samplesSynchronous PMPoor responseCellular and molecular determinants of limited anti-tumor immunity in chromophobe renal carcinoma (ChRCC).
Labaki C, Alchoueiry M, Bi K, Zhang L, Hobeika C, Bakouny Z, El Ahmar N, Matar S, Priolo C, Khabibullin D, Schindler N, Camp S, Saliby R, Saad E, Signoretti S, Van Allen E, Shukla S, Henske E, Choueiri T, Braun D. Cellular and molecular determinants of limited anti-tumor immunity in chromophobe renal carcinoma (ChRCC). Journal Of Clinical Oncology 2024, 42: 476-476. DOI: 10.1200/jco.2024.42.4_suppl.476.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsAnti-tumor immunityCell of originScRNA-seq dataPutative cell of originHLA class I genesCD8+Class I genesPD-1T cellsI geneSingle-cell T-cell receptorPoor responseResponse to immune checkpoint inhibitorsExpression of HLA class I genesInfiltration of CD8+Infiltration of T cellsCD4+ T cellsDegree of clonal expansionDownregulation of antigen presentationProportion of CD8+T cell clonotypesChromophobe renal carcinomaMolecular determinantsProtein processing pathway
2022
PI3K activation allows immune evasion by promoting an inhibitory myeloid tumor microenvironment
Collins NB, Al Abosy R, Miller BC, Bi K, Zhao Q, Quigley M, Ishizuka JJ, Yates KB, Pope HW, Manguso RT, Shrestha Y, Wadsworth M, Hughes T, Shalek AK, Boehm JS, Hahn WC, Doench JG, Haining WN. PI3K activation allows immune evasion by promoting an inhibitory myeloid tumor microenvironment. Journal For ImmunoTherapy Of Cancer 2022, 10: e003402. PMID: 35264433, PMCID: PMC8915320, DOI: 10.1136/jitc-2021-003402.Peer-Reviewed Original ResearchConceptsImmune evasionCheckpoint blockadePI3K activationMouse syngeneic tumor modelsPharmacological PI3K inhibitionEfficacy of immunotherapyNumber of CD8Tumor immune evasionTumor immune microenvironmentRational combination strategiesSyngeneic tumor modelsCell-extrinsic effectsK activationPI3K inhibitionMyeloid microenvironmentImmune microenvironmentPoor responseMyeloid infiltrationT cellsImmune responseImmunotherapyMyeloid cellsImmune systemPhospho-inositol-3 kinaseTumor microenvironment
2021
Blockade of the CD93 pathway normalizes tumor vasculature to facilitate drug delivery and immunotherapy
Sun Y, Chen W, Torphy RJ, Yao S, Zhu G, Lin R, Lugano R, Miller EN, Fujiwara Y, Bian L, Zheng L, Anand S, Gao F, Zhang W, Ferrara SE, Goodspeed AE, Dimberg A, Wang XJ, Edil BH, Barnett CC, Schulick RD, Chen L, Zhu Y. Blockade of the CD93 pathway normalizes tumor vasculature to facilitate drug delivery and immunotherapy. Science Translational Medicine 2021, 13 PMID: 34321321, PMCID: PMC8749958, DOI: 10.1126/scitranslmed.abc8922.Peer-Reviewed Original ResearchConceptsInsulin-like growth factor binding protein 7Vascular dysfunctionAnti-programmed death-1/Intratumoral effector T cellsTumor vasculatureTumor microenvironmentGrowth factor binding protein 7Tumor-associated endothelial cellsImproved antitumor responsesEffector T cellsDeath-1/Immune checkpoint therapyImmune cell infiltrationFavorable tumor microenvironmentMouse tumor modelsBinding protein 7Checkpoint therapyAntitumor responseCell infiltrationPoor responseT cellsHypoxic tumor microenvironmentTumor perfusionSolid tumorsTherapeutic interventionsCDKN2A Alterations and Response to Immunotherapy in Solid Tumors
Adib E, Nassar AH, Akl EW, Abou Alaiwi S, Nuzzo PV, Mouhieddine TH, Sonpavde G, Haddad RI, Mouw KW, Giannakis M, Hodi FS, Shukla SA, Gusev A, Braun DA, Choueiri TK, Kwiatkowski DJ. CDKN2A Alterations and Response to Immunotherapy in Solid Tumors. Clinical Cancer Research 2021, 27: 4025-4035. PMID: 34074656, PMCID: PMC8900067, DOI: 10.1158/1078-0432.ccr-21-0575.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsUrothelial carcinomaGenomic alterationsMemorial Sloan-Kettering Cancer CenterNon-small cell lungDana-Farber Cancer InstituteICI treatment outcomesPlatinum-based therapyTumor immune microenvironmentImmuno-inflammatory pathwaysRenal cell carcinomaDFCI cohortICI therapyCheckpoint inhibitorsCancer Genome AtlasClinical benefitCancer CenterCell carcinomaCell lungPredictive biomarkersDifferent cancer typesPoor responseWorse outcomesMSK-IMPACTMetastatic cancer
2020
Frailty in Critical Care Medicine: A Review.
De Biasio JC, Mittel AM, Mueller AL, Ferrante LE, Kim DH, Shaefi S. Frailty in Critical Care Medicine: A Review. Anesthesia & Analgesia 2020, 130: 1462-1473. PMID: 32384336, PMCID: PMC7426653, DOI: 10.1213/ane.0000000000004665.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsFrailty syndromeCare settingsDetermination of frailtyIntensive care patientsIntensive care unitHealth care utilizationAcute care settingCritical care settingClinical risk assessmentFrailty measurement toolsCritical care medicineAge-related accumulationCare patientsFrailty measurementRisk stratificationCare unitCare utilizationClinical entityPoor outcomePoor responsePrognostic trendObservational studyFunctional declineCare medicineMultisystem dysregulationPD39-06 POOR RESPONSE TO IMMUNOTHERAPY IS ASSOCIATED WITH HIGH EXPRESSION OF A NOVEL EPIDERMAL GROWTH FACTOR RECEPTOR SPLICE VARIANT IN PATIENTS WITH RENAL CELL CARCINOMA
Hajiran* A, Kim Y, Zaman S, Madanyake T, Robinson T, Falasiri S, Spiess P, Kohli M, Boyle T, Mulé J, Teer J, Manley B. PD39-06 POOR RESPONSE TO IMMUNOTHERAPY IS ASSOCIATED WITH HIGH EXPRESSION OF A NOVEL EPIDERMAL GROWTH FACTOR RECEPTOR SPLICE VARIANT IN PATIENTS WITH RENAL CELL CARCINOMA. Journal Of Urology 2020, 203 DOI: 10.1097/ju.0000000000000918.06.Peer-Reviewed Original Research
2019
The Immune Microenvironment in Hormone Receptor–Positive Breast Cancer Before and After Preoperative Chemotherapy
Waks AG, Stover DG, Guerriero JL, Dillon D, Barry WT, Gjini E, Hartl C, Lo W, Savoie J, Brock J, Wesolowski R, Li Z, Damicis A, Philips AV, Wu Y, Yang F, Sullivan A, Danaher P, Brauer HA, Osmani W, Lipschitz M, Hoadley KA, Goldberg M, Perou CM, Rodig S, Winer EP, Krop IE, Mittendorf EA, Tolaney SM. The Immune Microenvironment in Hormone Receptor–Positive Breast Cancer Before and After Preoperative Chemotherapy. Clinical Cancer Research 2019, 25: 4644-4655. PMID: 31061067, PMCID: PMC6677598, DOI: 10.1158/1078-0432.ccr-19-0173.Peer-Reviewed Original ResearchConceptsStromal tumor-infiltrating lymphocytesImmune microenvironmentNeoadjuvant chemotherapyPD-L1Breast cancerHormone receptor-positive breast cancerBreast tumorsHormone receptor-positive/HER2-negative breast cancerHER2-negative breast cancerDistant metastasis-free survivalReceptor-positive breast cancerImmunotherapy-based approachesPAM50 intrinsic subtypesCheckpoint inhibitor therapyPD-L1 stainingTumor-infiltrating lymphocytesMetastasis-free survivalMacrophage-targeted therapiesRole of macrophagesPreoperative chemotherapyStandard chemotherapyInhibitor therapyResidual diseaseMyeloid signaturePoor responseDiminished ovarian reserve versus ovarian aging: overlaps and differences.
Ata B, Seyhan A, Seli E. Diminished ovarian reserve versus ovarian aging: overlaps and differences. Current Opinion In Obstetrics & Gynecology 2019, 31: 139-147. PMID: 30870184, DOI: 10.1097/gco.0000000000000536.Peer-Reviewed Original ResearchConceptsNormal ovarian reserveOvarian reservePregnancy lossOocyte qualityReproductive technology cyclesAge-matched womenDiminished ovarian reserveLow ovarian reserveFetal chromosomal abnormalitiesQuantitative declineFecundity of womenOvarian stimulationNatural conceptionOvarian agingPoor responseART treatmentAged womenYoung womenChromosomal abnormalitiesAvailable evidenceDecreased numberQualitative declineOocyte poolWomenBlastocyst development
2018
DNA methylation-based age prediction and telomere length in white blood cells and cumulus cells of infertile women with normal or poor response to ovarian stimulation
Morin SJ, Tao X, Marin D, Zhan Y, Landis J, Bedard J, Scott RT, Seli E. DNA methylation-based age prediction and telomere length in white blood cells and cumulus cells of infertile women with normal or poor response to ovarian stimulation. Aging 2018, 10: 3761-3773. PMID: 30530921, PMCID: PMC6326671, DOI: 10.18632/aging.101670.Peer-Reviewed Original ResearchConceptsChronologic agePremature reproductive agingReproductive-age womenWhite blood cellsOvarian stimulationInfertile womenOvarian responsePatient ageInfertile patientsAge womenPoor responseFollicular somatic cellsReproductive agingFertility treatmentCumulus cellsBlood cellsTelomere lengthAgeWomenPatientsStimulationWBCFemale ageRiskReproductive senescenceDiminished ovarian reserve and poor response to stimulation in patients <38 years old: a quantitative but not qualitative reduction in performance
Morin SJ, Patounakis G, Juneau CR, Neal SA, Scott RT, Seli E. Diminished ovarian reserve and poor response to stimulation in patients <38 years old: a quantitative but not qualitative reduction in performance. Human Reproduction 2018, 33: 1489-1498. PMID: 30010882, DOI: 10.1093/humrep/dey238.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAneuploidyBlastomeresDatabases, FactualEmbryo Culture TechniquesEmbryo TransferFemaleFertility Agents, FemaleFertilization in VitroHumansInfertility, FemaleLive BirthOvarian ReserveOvaryOvulationOvulation InductionPregnancyPregnancy RateRetrospective StudiesTreatment OutcomeConceptsPoor oocyte qualityOvarian reserveLive birth rateDiminished ovarian reserveOocyte yieldOocyte qualityBlastulation rateAMH levelsPoor respondersPoor responseFollicular depletionBirth rateEmbryo transferAneuploidy rateLower live birth ratesYoung womenSTUDY FUNDING/COMPETINGGood prognosis patientsOvarian reserve parametersOvarian reserve testingYoung poor respondersPoor ovarian responseRetrospective cohort studyLower oocyte yieldInterquartile rangeAntenatal depression, psychotropic medication use, and inflammation among pregnant women
Miller E, Grobman W, Culhane J, Adam E, Buss C, Entringer S, Miller G, Wadhwa P, Keenan-Devlin L, Borders A. Antenatal depression, psychotropic medication use, and inflammation among pregnant women. Archives Of Women's Mental Health 2018, 21: 785-790. PMID: 29862416, PMCID: PMC6240365, DOI: 10.1007/s00737-018-0855-9.Peer-Reviewed Original ResearchConceptsAntenatal depressive symptomsInflammatory biomarkersPregnant womenProspective multicenter observational studyCross-sectional secondary analysisContext of pharmacotherapyHigher TNFα levelsMulticenter observational studyEpidemiologic Studies Depression ScalePsychotropic medication useLower TNFαPre-existing high levelsAntenatal depressionMedication useSerum TNFαTNFα levelsWeeks' gestationSelf-reported useDepression screenPsychotropic medicationsTNFα concentrationsMedical recordsPoor responseTherapeutic responseObservational study
2017
EIF1AX and NRAS Mutations Co-occur and Cooperate in Low-Grade Serous Ovarian Carcinomas
Etemadmoghadam D, Azar WJ, Lei Y, Moujaber T, Garsed DW, Kennedy CJ, Fereday S, Mitchell C, Chiew YE, Hendley J, Sharma R, Harnett PR, Li J, Christie EL, Patch AM, George J, Au-Yeung G, Mir Arnau G, Holloway TP, Semple T, Pearson JV, Waddell N, Grimmond SM, Köbel M, Rizos H, Lomakin IB, Bowtell DDL, deFazio A. EIF1AX and NRAS Mutations Co-occur and Cooperate in Low-Grade Serous Ovarian Carcinomas. Cancer Research 2017, 77: 4268-4278. PMID: 28646021, DOI: 10.1158/0008-5472.can-16-2224.Peer-Reviewed Original ResearchConceptsLow-grade serous ovarian carcinomaSerous ovarian carcinomaRAS pathway mutationsRAS pathway activationCoexpression of mutantWhole-genome sequencingTranslational regulatorOvarian cancerOvarian carcinomaPoor responseInitiation fidelityN-terminusGenome sequencingCancer ResMutational eventsPathway activationPathway mutationsClonogenic survivalMutationsRecurrent mutationsProteinChemotherapyOvarian reserve testing: a user’s guide
Tal R, Seifer DB. Ovarian reserve testing: a user’s guide. American Journal Of Obstetrics And Gynecology 2017, 217: 129-140. PMID: 28235465, DOI: 10.1016/j.ajog.2017.02.027.Peer-Reviewed Original ResearchConceptsOvarian reserve testingOvarian reserve testsOvarian reserveAntimüllerian hormoneDay 3 follicle-stimulating hormonePolycystic ovary syndromeFemale cancer patientsFollicle-stimulating hormoneFertility treatment optionsSelection of treatmentAntral follicular countAge-specific valuesGood predictive valueComplex clinical phenomenonOvarian hyperstimulationOvarian stimulationOvary syndromeGonadotoxic therapyTreatment optionsCancer patientsPoor responseReproductive ageFollicular countReproductive endocrinologistsTreatment protocolVanishing bile duct syndrome in Hodgkin’s lymphoma: A case report and literature review
Bakhit M, McCarty TR, Park S, Njei B, Cho M, Karagozian R, Liapakis A. Vanishing bile duct syndrome in Hodgkin’s lymphoma: A case report and literature review. World Journal Of Gastroenterology 2017, 23: 366-372. PMID: 28127210, PMCID: PMC5236516, DOI: 10.3748/wjg.v23.i2.366.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntineoplastic AgentsBile Duct DiseasesBile Ducts, IntrahepaticBiopsyCholangiopancreatography, Magnetic ResonanceCholestasisExomeHepatocyte Growth FactorHigh-Throughput Nucleotide SequencingHodgkin DiseaseHumansHyperbilirubinemiaHypertension, PortalJaundiceLiverLiver Function TestsMaleNeoplasm StagingProto-Oncogene ProteinsSyndromeTomography, X-Ray ComputedConceptsBile duct syndromeHodgkin's lymphomaIntra-hepatic bile ductsBile duct lossBile duct injuryAdverse drug reactionsDifferent pathologic conditionsTransplant evaluationDuct injuryAllograft rejectionClinical recoveryParaneoplastic phenomenonBiliary cirrhosisLiver biopsyLiver failureBile ductAutoimmune diseasesCase reportDrug reactionsEarly recognitionPhysical examPoor responseVBDSHumoral factorsMedical treatment
2016
Prognostic implications of epicardial fat volume quantification in acute pericarditis
Lazaros G, Antonopoulos AS, Oikonomou EK, Vasileiou P, Oikonomou E, Stroumpouli E, Karavidas A, Antoniades C, Tousoulis D. Prognostic implications of epicardial fat volume quantification in acute pericarditis. European Journal Of Clinical Investigation 2016, 47: 129-136. PMID: 27931089, DOI: 10.1111/eci.12711.Peer-Reviewed Original ResearchConceptsEpicardial fat volumeCardiac computerized tomographyComposite clinical endpointAcute pericarditisIncessant pericarditisChest painPrognostic implicationsClinical endpointsPoor responsePericardial effusion sizeOutcomes of patientsAtrial fibrillation developmentImportant prognostic implicationsCardiovascular disease pathogenesisAnti-inflammatory drugsLower odds ratioFifty patientsClinical featuresEffusion sizeFirst diagnosisPrognostic informationOdds ratioPericarditisFat volumePatientsEfficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis
D'Angelo SP, Larkin J, Sosman JA, Lebbé C, Brady B, Neyns B, Schmidt H, Hassel JC, Hodi FS, Lorigan P, Savage KJ, Miller WH, Mohr P, Marquez-Rodas I, Charles J, Kaatz M, Sznol M, Weber JS, Shoushtari AN, Ruisi M, Jiang J, Wolchok JD. Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis. Journal Of Clinical Oncology 2016, 35: 226-235. PMID: 28056206, PMCID: PMC5559888, DOI: 10.1200/jco.2016.67.9258.Peer-Reviewed Original ResearchConceptsMedian progression-free survivalObjective response rateProgression-free survivalMucosal melanomaCutaneous melanomaNivolumab monotherapyAnti-programmed death-1 therapyResponse rateTreatment-related adverse eventsSafety of nivolumabPhase III trialsRare melanoma subtypeNivolumab AloneAdverse eventsIII trialsSafety profileAggressive malignancyCombination therapyConventional therapyPooled analysisPoor responseClinical studiesGrade 3IpilimumabMelanoma subtypesRisk of metastasis and orbital recurrence in advanced retinoblastoma eyes treated with systemic chemoreduction versus primary enucleation
Berry JL, Kogachi K, Aziz HA, McGovern K, Zolfaghari E, Murphree AL, Jubran R, Kim JW. Risk of metastasis and orbital recurrence in advanced retinoblastoma eyes treated with systemic chemoreduction versus primary enucleation. Pediatric Blood & Cancer 2016, 64: e26270. PMID: 28221729, PMCID: PMC7034314, DOI: 10.1002/pbc.26270.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsCarboplatinCombined Modality TherapyEtoposideEye EnucleationFemaleFollow-Up StudiesHumansInfantMaleNeoplasm Recurrence, LocalNeoplasm StagingOrbital NeoplasmsPrognosisRetinal NeoplasmsRetinoblastomaRetrospective StudiesRisk FactorsSalvage TherapyVincristineConceptsPrimary enucleation groupSystemic chemoreductionHigh-risk pathologyMetastatic diseaseOrbital recurrencePrimary enucleationAdvanced retinoblastomaEnucleation groupTreatment failureHigh-risk pathologic featuresChildren's Hospital Los AngelesPrimary outcome measureRisk of metastasisSalvage therapySecondary enucleationRetrospective reviewE retinoblastomaMedian timePathologic featuresRetinoblastoma eyesTreatment modalitiesPoor responseOutcome measuresChemoreductionSubsequent enucleationComparative Effectiveness of Diabetic Oral Medications Among HIV-Infected and HIV-Uninfected Veterans
Han JH, Gordon K, Womack JA, Gibert CL, Leaf DA, Rimland D, Rodriguez-Barradas MC, Bisson GP. Comparative Effectiveness of Diabetic Oral Medications Among HIV-Infected and HIV-Uninfected Veterans. Diabetes Care 2016, 40: 218-225. PMID: 27634393, PMCID: PMC5250696, DOI: 10.2337/dc16-0718.Peer-Reviewed Original ResearchMeSH KeywordsAdultBlack or African AmericanBlood GlucoseBody Mass IndexComparative Effectiveness ResearchDiabetes Mellitus, Type 2FemaleFollow-Up StudiesGlycated HemoglobinHispanic or LatinoHIV InfectionsHumansHypoglycemic AgentsLongitudinal StudiesMaleMetforminMiddle AgedSulfonylurea CompoundsThiazolidinedionesVeteransWhite PeopleConceptsType 2 diabetesDiabetic medicationsHIV infectionHispanic patientsPoor responseGlycemic responseOral diabetic medicationsLongitudinal cohort studyBaseline HbAGlycemic effectivenessHIV-InfectedUninfected veteransMedication initiationCohort studyOral medicationsWhite patientsPotential confoundersClinical covariatesMedicationsHIVPatientsType 2Comparative effectivenessPropensity scoreDiabetes
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply